Galderma the pureplay dermatology category leader will be showcasing its latest clinical and educational efforts at the American Academy of Dermatology AAD Annual Meeting from March 812 2024 highlighting its broad innovative and leading dermatology portfolio.
Jonathan Silverberg, MD, PhD, MPH, of George Washington University School of Medicine and Health Sciences, explains the benefits of using Janus kinase (JAK) inhibitors to treat patients with atopic dermatitis (AD).
Our top coverage from this year’s Revolutionizing Atopic Dermatitis (RAD) conference highlighted the evolving therapy landscape for patients with AD.